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Abstract
Background—There is controversy regarding the definition and characteristics of mild cognitive
impairment in Parkinson’s disease.
Objective—The Movement Disorders Society commissioned a Task Force to critically evaluate
the literature and determine the frequency and characteristics of Parkinson’s disease-mild
cognitive impairment and its association with dementia.
Methods—Comprehensive PubMed literature review using systematic inclusion and exclusion
criteria.
Results—A mean of 26.7% (range, 18.9–38.2%) of non-demented Parkinson’s disease patients
have mild cognitive impairment. The frequency of Parkinson’s disease mild cognitive impairment
increases with age, disease duration, and disease severity. Impairments occur in a range of
cognitive domains, but single domain impairment is more common than multiple domain
impairment, and within single domain impairment, non-amnestic is more common than amnestic
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impairment. A high proportion of patients with Parkinson’s disease-mild cognitive impairment
progress to dementia in a relatively short period of time.
Conclusions—The primary conclusions of the Task Force are that: (1) Parkinson’s disease-mild
cognitive impairment is common; (2) there is significant heterogeneity within Parkinson’s disease-
mild cognitive impairment in the number and types of cognitive domain impairments; (3)
Parkinson’s disease-mild cognitive impairment appears to place patients at risk of progressing to
dementia; and (4) formal diagnostic criteria for Parkinson’s disease-mild cognitive impairment are
needed.
Keywords
mild cognitive impairment; Parkinson’s disease; systematic review
INTRODUCTION
Cognitive impairment is common in Parkinson’s disease (PD), with long-term longitudinal
studies reporting that most PD patients develop dementia (PDD).1–3 The impact of PDD is
substantial, with major consequences for functioning,4, 5, 6 nursing home admission,7
psychiatric morbidity,8 caregiver burden 9, 10 and mortality.11, 12
Mild cognitive impairment in PD (PD-MCI), defined as a cognitive decline that is not
normal for age but with essentially normal functional activities, also appears to be common,
even at the time of PD diagnosis and prior to initiation of dopaminergic therapy.13 Although
the term MCI applied to PD is not without controversy,14, 15 it is more frequently used and
more widely accepted than alternative terms. Identifying PD-MCI is important clinically, as
these patients appear to be at increased risk for developing PDD.16 The biological validity of
PD-MCI is supported by preliminary structural17 and functional18, 19 neuroimaging,
electroencephalography,20, 21 genetic,22, 23 cerebrospinal fluid,24–26 and autopsy studies27
showing an association between a range neuropathophysiological variables and either
cognitive impairment or cognitive decline in non-demented PD patients. From a scientific
standpoint, studying PD-MCI offers insight into the neural substrate of the earliest stage of
cognitive decline in PD that may lead to early intervention and may guide drug development
focused on preventing or delaying the onset of PDD.
In spite of what is known about PD-MCI, the heterogeneity of cognitive deficits from the
initial stages of the disease and the relative scarcity of longitudinal studies have made it
difficult to definitively determine the following: (1) whether there are different and
reproducible subtypes of PD-MCI; (b) what proportion of PD-MCI patients progress to
PDD; (3) whether the term MCI can be defined and operationalized in PD to determine
those patients at imminent risk of PDD; and (4) whether this risk differs on the basis of MCI
subtype.
Given the critical importance of having uniform criteria for PD-MCI both for the
identification and management of PD patients and for future therapeutic trials, the
Movement Disorders Society (MDS) commissioned a Task Force to: (1) critically evaluate
the literature; (2) more accurately determine the frequency and characteristics of PD-MCI
and its conversion rate to PDD; and (3) propose formal diagnostic criteria for PD-MCI. The
present paper deals with the first two of these issues since they are necessary to address prior
to proposing new criteria. Criteria and guidelines for the definition and ascertainment of
MCI in PD based on the present “state of the art” will be addressed in a future manuscript.
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Literature Search and Selection of Articles
A comprehensive review of the literature through September 1, 2010 was conducted through
Medline (PubMed) using combined free search terms that included “Parkinson,” “cognitive
impairment,” and “mild cognitive impairment.” The search was limited to empirical
English-language articles. The search retrieved 984 articles using the key terms “Parkinson
and cognitive impairment” and 172 articles using “Parkinson and mild cognitive
impairment,” with most of the latter articles already retrieved in the first search.
Abstracts (or papers when abstracts lacked information on inclusion and exclusion criteria)
were further scrutinized to include only those reports that fit study inclusion criteria: (1) a
minimum of 100 non-demented PD patients in cross-sectional studies, or 50 patients in
prospective studies; (2) presence of quantitative neuropsychological information covering at
least three of five cognitive domains: memory, executive, attention/working memory,
visuospatial, and language; and (3) comparison of PD to a local control group or use of
normative values. Exclusion criteria were: (1) lack of definition of impaired cognition or
dementia, review articles, guidelines, meta-analyses, clinical therapeutic trials (unless the
trial was negative), and (2) cognitive studies in demented or surgically-treated PD patients
and in other neurological diseases, and articles focused on depression, REM sleep behavior
disorder, olfactory dysfunction, impulse control disorders or psychosis without relevant
cognitive data. Articles with abstracts that did not disclose all inclusion/exclusion criteria
explicitly were included for further review.
Forty-eight articles met study inclusion criteria based on the review. The 48 articles were
reviewed by five pairs of Task Force members (approximately 10 articles per pair) who
independently extracted key data from the identified articles.1, 3, 12, 13, 16, 28–70 The most
common reasons for exclusion were lack of definition of impaired cognition or failure to
explicitly exclude patients with
dementia, 1, 3, 29, 30, 33, 36, 42, 44–46, 48, 49, 51, 55–57, 59, 62, 64, 66, 67 sample size not meeting
inclusion criteria 31, 32, 35, 37, 52, 58, 60, 71, 72, or evaluation of less than 3 domains of
cognition. 3, 12, 61, 63, 65, 69
Data Extraction and Quality Assessment
The Task Force members rated the manuscripts using a structured form that included: (1)
type of study (random, door-to-door; multiple sources; hospital based); (2) number of PD
patients and percentage of patients with MCI, (3) demographics; (4) diagnostic criteria for
PD, MCI, and PDD; (5) neuropsychological tests utilized; (6) number of cognitive domains
tested; and (7) the presence of a normal control group or use of tests with normative values.
For our final analysis we selected articles that had clearly defined cognitive and PD
diagnostic criteria, studied at least three cognitive domains with standard versions of
published neuropsychological tests, either included a control group matched by age and
education evaluated with the same protocol or utilized test normative values to define MCI,
and did not include the same study population as another study (except for prospective
studies).
RESULTS
A total of 8 papers met all the inclusion/exclusion criteria. The studies included a total of
776 PD patients from 6 cross-sectional studies and 198 from 2 prospective studies (Table 1)
and varied widely regarding design, population, and criteria and methods for defining MCI
and dementia.
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Table 2 shows the neuropsychological tests and domains explored, MCI criteria used, and
MCI subtypes found in each study. Overall, the studies demonstrate that PD-MCI is
common in PD patients without dementia (mean cross-sectional prevalence =26.7%, range
=18.9–38.2%), its frequency increases with age and duration of PD, single domain
impairment is more common than multiple domain impairment, and in the case of single
domain impairment, non-amnestic MCI is more common than amnestic MCI.
Aarsland et al.28 evaluated a community-based incident cohort of 196 non-demented, drug-
naïve PD patients73 and 201 healthy controls (HC). The neuropsychological battery
measured global cognition with the Mini-Mental State Examination (MMSE) and evaluated
three cognitive domains with additional neuropsychological testing. The authors calculated
z-scores for the PD patients based on control data. They categorized MCI cases into one of
four subtypes (Table 2). Compared with HC, PD patients were impaired on all
neuropsychological tests, and 18.9% met criteria for MCI (Table 1), with a risk ratio (RR) of
2.1 compared with controls. Older PD patients (≥65 years) had a higher RR (2.6) of having
MCI than younger cases (<65 years; RR=1.5).
Foltynie et al.34 assessed cognitive function in an incident cohort of 159 PD patients.74
Thirteen (8%) of the patients74 scored <24 on MMSE and were considered to have
dementia, even though dementia at diagnosis was an exclusion criterion. Of the remaining
146 cases, 142 were included in the study, and more than one-third were considered
cognitively impaired, defined as scoring ≥1 SD below the normative mean in a pattern
recognition task (temporal lobe impairment), the Tower of London task (fronto-striatal
impairment), or on both tests (global impairment). The term “MCI” was not used in this
study.
Hoops et al.40 compared the discriminant validity of the Montreal Cognitive Assessment
(MoCA) and MMSE at diagnosing MCI in PD, using a neuropsychological test battery as a
gold standard. Among a convenience sample of 132 PD cases at a movement disorders
clinic,73 12.9% had PDD and 20% had MCI based on a test battery that evaluated four
cognitive domains.
Mamikonyan et al.,47 explored the cognitive performance of 106 PD patients (a convenience
sample at a movement disorders clinic), who had intact global cognition based on ther age-
and education-adjusted MMSE score. Thirty-one patients (29.2%) were classified as having
MCI, defined as scoring ≥1.5 SD below the normative data in at least one of the three
domains assessed. The authors concluded that cognitive impairment is frequent in PD
patients with normal cognition based on MMSE score, and that memory deficits are
common at the stage of PD-MCI.
Muslimovic et al.,13 studied 115 PD patients without “global cognitive deterioration”
defined as MMSE score <24 and 70 elderly HC in one of the most detailed investigations of
cognition in non-demented PD patients. A comprehensive battery of 28 neuropsychological
tests was administered, and PD patients were significantly impaired on 20 of these. Twenty-
seven patients (23.5%) were cognitively impaired, defined as scoring ≥2 SD below the
normative mean on ≥3 cognitive tests, compared with 4% of HC. The domains most
commonly impaired were attention/executive function, psychomotor speed and memory.
Pai et al.,53 studied cognitive abilities in 102 non-demented PD patients recruited from a
behavioral clinic. They used the Chinese version of the Cognitive Ability Screening
Instrument (CASI), a comprehensive screening instrument with normative data that includes
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subscores for five cognitive domains. They found that 38.2% fulfilled MCI criteria, defined
as ≥1.5 SD below the mean in at least one subtest.
Longitudinal Studies
One of the studies reviewed68 included the longitudinal assessment of patients on whom
baseline data was reported in the cross-sectional studies selected above. 34 Janvin et al.16
conducted a longitudinal study of cognitive function in a community-based sample of 145
PD cases. Cases and controls were assessed at baseline and at 4 years. Patients with MMSE
score <25 at baseline were considered demented and excluded. Of the 145 original cases, 72
PD non-demented cases were studied and compared to 38 HC. After four years, for those
who completed follow-up, dementia developed in 18/29 (62.0%) of patients with PD-MCI at
baseline, compared with 6/30 (20.0%) of PD patients with normal cognition at baseline. This
sample consisted of established PD patients, explaining the higher overall conversion rate to
PDD over the same time period used in the CamPaign study (see below). The proportion
converting to PDD was numerically higher among those with single domain non-amnestic
MCI (69%) compared to amnestic MCI (40%), and in a logistic regression analysis this MCI
subtype at baseline predicted PDD development. The authors concluded that PD-MCI is a
risk factor for developing PDD.
Williams-Gray et al.,68 reassessed 126 non-demented PD patients between 3–5 years after
their baseline evaluation, and found that 10% developed PDD over this time period. In this
first wave of follow-up, older age, non-tremor dominant phenotype, higher Unified
Parkinson’s Disease Rating Scale motor scores, and below average performance on tests of
semantic fluency, pentagon copying, spatial recognition memory, and Tower of London
were associated with a more rapid rate of decline on the MMSE and progression to PDD.
The authors concluded that posterior cortical cognitive deficits increased the risk for the
development of PDD, whereas fronto-striatal cognitive deficits did not.
DISCUSSION
The results of our systematic literature search and review are that: (1) an average of 26.7%
(range 18.9–38.2%) of non-demented PD patients have PD-MCI; (2) cognitive deficits can
be detected in some patients even at the time of PD diagnosis; (3) the frequency of MCI
increases with age, and duration and severity of PD; (4) impairments can occur in a range of
cognitive domains; (5) non-amnestic single domain MCI is more common than amnestic
single domain MCI; and (6) PD-MCI appears to be a risk factor for the development of
PDD.
Prevalence and Correlates
The majority of PD patients will develop dementia.3, 22 The point prevalence of PDD is
approximately 30%, 75 and the cumulative prevalence is at least 75% for PD patients
surviving more than 10 years.2, 3 As MCI precedes PDD, the cumulative prevalence of PD-
MCI must be at least as high as that of PDD. Consequently, our finding that approximately
27% of PD patients meet criteria for PD-MCI at any given time is not surprising. Our results
are similar to those recently reported by Aarsland et al.,76 who used a common methodology
for the definition of MCI on pooled data of over 1,000 non-demented PD patients from
multiple centers, and found that 25.8% (23.5–28.2%) had MCI.
The lowest proportion of patients with MCI was found in a study of patients at early PD
stages,13 and the highest proportion in studies including cases with more advanced disease
severity and duration.16, 68, 76 The variation in MCI frequency present in the articles
reviewed also reflects differences in methodology (e.g., study settings and populations,
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recruitment methods, MCI diagnostic criteria, number of cognitive domains assessed,
number of tests used for each domain, and how impairment on a test was defined). The fact
that cognitive deficits in PD are detectible in some patients even at the time of clinical
diagnosis highlights complexities in differentiating PD from dementia with Lewy bodies
(DLB).
The correlates of PD-MCI have not been studied extensively. Of the studies included in this
review, there was evidence that increasing age, 34, 47 more severe PD, 34, 47 late onset of
disease, 13 and lower educational levels 53 were associated with PD-MCI.
Profile of Cognitive Impairment
Although the cognitive deficits in PD have traditionally been classified as being
“subcortical” in nature77 (i.e., relatively greater impairments in executive abilities,
information processing speed, and working memory compared with episodic memory
storage and language), our review showed that a range of cognitive domains are impaired in
PD patients without dementia. Other research in PD has demonstrated deficits in executive
(i.e., impaired planning and working memory),78 visuospatial,79 attentional,80 memory,81
and even language abilities.82–85
In all of the studies reviewed herein, single domain MCI was more common than multiple
domain MCI, and non-amnestic MCI was more common than amnestic MCI in patients with
impairment in a single domain. Debate exists about the extent to which the mild memory
and language deficits in PD are secondary to executive and working memory problems.
Additionally, as prospective studies using formal definitions for MCI subtypes are almost
non-existent, the usefulness and predictive value of this PD-MCI classification structure is
currently hypothetical.
Epidemiology of Progression from PD-MCI to Dementia
The few longitudinal studies of non-demented PD patients find that 20–60% develop PDD
over a period of 2–5 years,22, 46, 76, 86–89 and even newly diagnosed PD patients on average
experience significant decline in a range of cognitive domains over a several-year
period.49,90 The finding that PD-MCI patients are at higher risk for developing dementia is
consistent with a clinico-pathologic study reporting cognitive impairment in the earliest
stages of clinically manifested PD, possibly related to changes in brainstem monoaminergic
nuclei or early involvement of forebrain cholinergic nuclei.91
Preliminary research suggests that the majority of PD-MCI cases convert to PDD over a
several-year period.16, 22, 68 The two longitudinal studies included in this review differed in
terms of design and methodology. Williams-Gray et al.68 followed an incident cohort of
non-demented PD patients in two waves, but did not specifically examine progression from
a state of “mild impairment” to PDD. The focus of this research to date has been to
determine which demographic (increasing age), neuropsychological (semantic verbal
fluency and visuospatial deficits), and genetic factors (MAPT H1/H1 tau genotype) predicted
conversion to PDD at the second wave of follow-up22. The other study used a cross-
sectional sample of survivors from a prevalence sample.16 In this study, Janvin et al. found
that 62% of PD-MCI patients converted to PDD over a 4-year period, compared with 20%
of PD patients with normal cognition. The frequency of conversion to PDD over a 4-year
period was: multiple domain MCI (63%), single, non-memory domain MCI (69%), single
domain, amnestic MCI (40%), and normal cognition (20%).
Regarding other risk factors, in one of the longitudinal studies reviewed increasing severity
of depression was associated with an increased risk of conversion from PD-MCI to PDD.16
In other research not covered in this manuscript, demographic and clinical correlates or risk
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factors for PDD development have included older age, male sex, lower educational level,
longer duration of PD, and greater motor impairment.22, 64, 83, 86, 90, 92, 93
Clinical Impact
PD-MCI appears to be a clinically significant syndrome, as even mild cognitive deficits or
self-rated cognitive deficits in early PD are associated with functional impairment5, 94 and
worse quality of life (QoL).95, 96 Thus, identification and intervention at the earliest stage of
PD-MCI is a crucial unmet need for the overall care of PD patients. The high frequency of
MCI in PD highlights the need for clinicians to routinely screen for cognitive impairment in
PD, as the results, including their prognostic implications, may influence clinical decision-
making. However, research in this area is preliminary, and additional studies are needed to
validate measures that are sensitive to initial changes in independent activities of daily living
(IADLs), QoL and interpersonal relationships that can occur at the stage of PD-MCI.
Complexities in the Assessment of Cognition in PD
Assessment of cognition in PD can be complicated by disease or medication-related effects,
such as bradykinesia, fatigue, sleepiness, and mood disorders, which can adversely impact
test results regardless of cognitive abilities. Specifically, motor slowing (i.e., bradykinesia)
and resting or intentional tremor may lead to impaired performance on any timed test, while
tremor can interfere with performance on any test requiring motor abilities (e.g., use of a
pencil to complete a task). However, there has been very little research examining the
impact of these factors on cognitive performance specifically.
Another issue is that the definition of MCI forces a dichotomization (present-absent) of a
continuous variable (cognitive test performance), and debate continues regarding the
appropriate cut-off score and number of tests used to define PD-MCI. Caviness et al.32
reported that 21% of subjects had PD-MCI if an abnormality on multiple tests within a
domain was required, but this rose to 42% if an abnormality on only one test was required.
There is concern that the commonly-used definitions of MCI may lack sensitivity to detect
early cognitive decline (rather than impairment) in high functioning persons.97 Persons
functioning at a high level (i.e., above average) premorbidly have to experience sizeable
declines before scoring at least 1.5 SD below normative means. Consequently, a
considerable proportion of such patients with cognitive decline would be classified as
having “normal cognition.” While it can be argued that high premorbid functioning protects
against MCI in much the same manner as it does against dementia, this argument ignores the
fact that high functioning persons may be in more demanding work or social settings in
which even small cognitive declines translate into subtle functional impairments. On the
other hand, a key feature in diagnosing MCI pertains to a change in cognition. Thus, MCI is
not just a value on a cognitive test relative to the mean; rather, it is critical that the person
has experienced a change in cognition compared with baseline.
Additional unresolved issues are whether cognitive decline in PD is linear and whether
different profiles of cognitive deficits may have a different evolution and prognosis.
Previous studies have noted that time to PDD diagnosis is highly variable98 and that
cognitive changes after relatively long-term follow-up are not too consistent.97 Although a
distinct evolution of different cognitive domains cannot be inferred from a study using only
the MMSE, the re-analysis of data from a long-term prevalence study identified a variation
in the slope of decline, specifically a rapid cognitive deterioration after a relatively stable
period.99 These data should be examined in light of neuroimaging18, 19 and clinical52, 68
data showing that the transition from MCI to dementia in PD is characterized by the addition
of posterior cortical deficits upon frontal-subcortical ones.
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None of the reviewed papers examined biomarkers specifically as they pertain to PD-MCI.
One of the incident cohorts included in this review underwent a second wave follow-up, 22
and in that research the tau MAPT H1/H1 genotype (but not COMT genotype) was found to
be a risk factor for PDD, a finding recently confirmed.22 Other genetic polymorphisms (e.g.,
COMT polymorphisms and BDNF Val66Met genotype 100, 101) have been shown to be
associated with impairments in specific cognitive domains or abilities in PD. Several CSF
biomarkers for cognitive decline in PD have been proposed.102 Recent research suggests
decreased CSF β-amyloid (Aβ) 1–42 is associated with the early stages of cognitive decline
in PD.24, 26 This decrease might be due to specific Aβ plaque pathology, but it may be
nonspecific, as Aβ 1–42 has been shown to be decreased in neurodegenerative disorders
lacking distinct plaque pathology103–105 and in vivo plaque imaging (PET imaging with the
Aβ-binding Pittsburgh Compound B) shows no correlation between the plaque load and
cognition in PD. 106 Instead, the findings suggest a different mechanism of Aβ processing,
perhaps due to synaptic α-synuclein pathology. 107, 108 Structural neuroimaging, including
diffusion tensor imaging, have reported white matter abnormalities in non-demented PD
patients.108 In another study17 that classified patients as PD normal cognition (PD-NC), PD-
MCI, or PDD and used two different imaging analyses, PD-MCI patients compared with
PD-NC either had reduced gray matter in the prefrontal cortex and temporal lobes,17 or were
found to have similar regional brain volumes. Using FDG-PET, a PD-related cognitive
pattern in non-demented PD patients has been reported, characterized by metabolic
reductions in frontal and parietal association areas, and relative increases in the cerebellar
vermis and dentate nuclei.109 The pattern predicted memory and visuospatial performance,
and in a subsequent study single domain MCI patients had a PD-related cognitive pattern
expression intermediate (but not statistically significantly different) between normal and
multiple domain MCI patients.18 Clearly there is a need for the prospective and longitudinal
assessment of accessible biomarkers (including CSF, blood, and neuroimaging) and
neuropathological examination to further address this issue.
Conclusions and Future Directions
There has been limited research on the epidemiology and prognostic utility of PD-MCI as a
clinical syndrome. Nonetheless, the studies selected for review here, and other studies of
PD-MCI not meeting inclusion criteria, yield relatively consistent prevalence estimates of
MCI and its subtypes. They also show that single domain MCI is more common than
multiple domain MCI, and that non-amnestic, single domain MCI is more common than
amnestic, single domain MCI.
The Task Force has used this critical review of the literature and consensus of experts to
formulate PD-MCI diagnostic criteria that will be published separately. Once diagnostic
criteria for PD-MCI are proposed, prospective studies enrolling subjects with a wide range
of pre-morbid ability will be needed to examine the predictive value of both MCI overall
and MCI subtypes. Intervention trials can target MCI as a clinical syndrome, perhaps
stratifying MCI by subtype to determine if particular interventions (pharmacological vs.
behavioral) have differential acute or long-term effects. Although it is not known if or how a
diagnosis of PD-MCI should impact clinical management, at a minimum these patients
should be carefully monitored for ongoing cognitive decline.
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